Search results
Our iconic brands have a new home where thoughtful everyday care meets scientific precision. As a global consumer health leader, Kenvue touches the lives of more than a billion people across the globe.
Sep 28, 2022 · Kenvue Post-Separation: A Leading Global Consumer Health Company with Iconic Brands and Commitment to Continued Innovation. Kenvue will become a standalone leading global consumer health company in 2023, subject to legal requirements including consultation with works councils and employee representatives, as required.
Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue is the proprietor of well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Mylanta, Neutrogena, Trosyd, Tylenol, and Visine.
Jul 31, 2023 · If you’ve heard of Kenvue, you may already know that we’re a global consumer health company. But beyond our portfolio of iconic brands, Kenvue is built on a foundation of core values, which fuel our 22,000+ global team members every day. Here’s what you need to know: 1. You already know us
Through our iconic Kenvue brands, we connect with ~1.2 billion people globally in their daily rituals and the moments that matter most.
May 3, 2023 · J&J's consumer health spinoff, Kenvue, is expected to set an initial public offering price Wednesday night and trade Thursday on the New York Stock Exchange.
Kenvue is the world’s largest pure-play consumer health company by revenue. Built on more than a century of heritage and propelled forward by science, our iconic brands — including Aveeno ...
Sep 28, 2022 · Kenvue Post-Separation: A Leading Global Consumer Health Company with Iconic Brands and Commitment to Continued Innovation
Learn how Kenvue can help healthcare professionals provide the best care for their patients and communities.
May 4, 2023 · Johnson & Johnson’s consumer-health spinoff Kenvue started trading on the New York Stock Exchange under the stock ticker KVUE. Thursday’s move values the new company at roughly $50 billion ...
